Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008 Results

Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008
Results
Thursday, June 12th, 11:00 a.m. EDT

WALTHAM, Mass., June 6 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that the Company President and Chief Executive
Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on
Thursday, June 12th, 2008 at 11:00 a.m. EDT, to report fourth quarter and
fiscal year 2008 financial results and to provide a quarterly update of the
Company. Dr. Herlihy will be joined on the call by Dr. Gary Sachs, the
founder and director of the Bipolar Clinic and Research Program at
Massachusetts General Hospital and an Associate Professor of Psychiatry at the
Harvard Medical School to discuss Repligen's RG2417 program for bipolar
disorder.
This call is being webcast by Thomson/CCBN and can be accessed via
Repligen's website at http://www.repligen.com. If you are unable to access
the webcast via the internet, you may also listen to the live broadcast by
calling (800) 261-3417 for domestic calls and (617) 614-3673 for international
calls. Participants must provide the following passcode: 34058699. For those
who cannot participate in the live conference call, an archive of the audio
webcast will be available shortly after the call and may be accessed at
http://www.repligen.com.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on the
development of novel therapeutics for neurological disorders. In addition, we
are the world's leading supplier of recombinant Protein A, the sales of which
partially fund the advancement of our development pipeline while supporting
our financial stability. Repligen's corporate headquarters are located at 41
Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional
information may be requested from http://www.repligen.com.
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The forward-looking statements in this release do not constitute
guarantees of future performance. Investors are cautioned that statements in
this press release which are not strictly historical statements, including,
without limitation, statements regarding current or future financial
performance and position, management's strategy, plans and objectives for
future operations, plans and objectives for product development, plans and
objectives for present and future clinical trials and results of such trials,
plans and objectives for regulatory approval, litigation, intellectual
property, product development, manufacturing plans and performance such as the
anticipated growth in the monoclonal antibody market and our other target
markets and projected growth in product sales, constitute forward-looking
statements. Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ materially from
those anticipated, including, without limitation, risks associated with: the
success of current and future collaborative relationships, the market
acceptance of our products, our ability to compete with larger, better
financed pharmaceutical and biotechnology companies, new approaches to the
treatment of our targeted diseases, our expectation of incurring continued
losses, our uncertainty of product revenues and profits, our ability to
generate future revenues, our ability to raise additional capital to continue
our drug development programs, the success of our clinical trials, our ability
to develop and commercialize products, our ability to obtain required
regulatory approvals, our compliance with all Food and Drug Administration
regulations, our ability to obtain, maintain and protect intellectual property
rights for our products, the risk of litigation regarding our intellectual
property rights, our limited sales and manufacturing capabilities, our
dependence on third-party manufacturers and value added resellers, our ability
to hire and retain skilled personnel, our volatile stock price, and other
risks detailed in Repligen's filings with the Securities and Exchange
Commission. Repligen assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
announcements described herein.
SOURCE Repligen Corporation

Walter C. Herlihy, Ph.D., President and Chief Executive Officer,
+1-781-419-1900, or Laura Whitehouse, Vice President, Market Development,
+1-781-419-1812, both of Repligen Corporation